Advertisement

BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 600x60px
Document › Details

DVS Sciences, Inc.. (7/14/11). "Press Release: DVS Sciences Raises $14.6 Million in Series A Financing to Advance Commercialization of Novel Single-cell Analysis Technology. Investors include 5AM Ventures, Pfizer Venture Investments, Mohr Davidow Venture

Region Region North America
Organisations Organisation DVS Sciences Inc.
  Group Fluidigm (Group)
  Organisation 2 5AM Ventures
Products Product CyTOF® mass cytometer
  Product 2 venture capital
Index terms Index term DVS Sciences–SEVERAL: investment, 201107 financing round Series A $14.6m 5AM Ventures + Pfizer Venture + Mohr Davidow + Roche Venture et al
  Index term 2 DVS Sciences–College Group: public relations, 201107 service existent by College Hill Life Sciences
Person Person Tanner, Scott (Univ Toronto 200911 + DVS Sciences 200911 CEO + co-founder)
     


DVS Sciences, Inc., a privately held innovator and manufacturer of highly multi-parameter single-cell analyzers and reagents for biological research and clinical applications, announced today that it has secured US $14.6 million in a Series A venture financing round. The proceeds will be used to accelerate the company's commercial manufacturing scale-up of its paradigm-shifting multi-parameter single cell analysis solution.

DVS Sciences, based in Ontario, Canada and Sunnyvale, California is a spin-off from the University of Toronto. The financing comes from a combination of investors that include 5AM Ventures, Pfizer Venture Investments, Mohr Davidow, the Roche Venture Fund and the Ontario Institute for Cancer Research.

"DVS Sciences has made great strides in demonstrating the significant demand for quantitative, highly multiparametric biomarker assays performed in single cells and we are pleased to be part of this significant Series A financing. The company is well positioned for high growth and to expand the cellular analysis marketplace," said Andrew Schwab, Managing Partner, 5AM Ventures. "We believe that the CyTOF® - MAXPAR® platform will transform the performance of cellular analysis. By enabling the measurement of many biomarkers simultaneously in single cells, researchers will be primed to better understand the cellular dynamics of disease states, stem cells and other biologically relevant systems."

The complete solution comprises a high-throughput mass cytometer for individual cell analysis, CyTOF, and a suite of MAXPAR reagents, which include stable-isotope-tagged antibodies. Functionally advanced when compared to current state-of-the-art flow cytometers, the CyTOF technology eliminates the inherent spectral overlap issues and enables quantitative, highly multi-biomarker analysis for scientific research, with potential applications in clinical trials and personalized medicine. Biological samples are labeled with MAXPAR tags and analyzed using the CyTOF technology to simultaneously identify up to 100 biomarkers with very high resolution and wide dynamic range. The CyTOF - MAXPAR system is specifically built for biologists and single cell applications and addresses a critical need for improving the quantitative detection and characterization of biomarkers and disease states (e.g., cancer stem cells).

Researchers at Stanford University, led by professor of microbiology and immunology Garry Nolan, Ph.D., demonstrated the effectiveness of the CyTOF Mass Cytometer in a study recently published in the journal Science (Bendall, et. al. Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum. Science, 2011; 332 (6030): 687-696). The project was focused on a 34-parameter bone marrow immunological and functional assay where subtle transitions between cell states were shown. Dr. Nolan, who was a senior author of the paper, commented that, "Using this technology, we can tell not only what kind of cell it is, but essentially what it's thinking, what it's been doing, and what it may soon do or become."

"This significant Series A financing puts us in a position to broadly commercialize our innovative instrumentation and reagents and help scientists accelerate biomedical research, delivering a quantum step towards personalized therapeutic diagnosis and prognosis, and transform drug discovery," said Scott Tanner, Ph.D., CEO and Co-Founder of DVS Sciences. "By enabling the simultaneous detection of up to 100 disease markers in single cells, the CyTOF technology is an important tool in providing a dramatic increase in the information data rate and determining a personalized signature of disease, which will be useful in guiding diagnosis and treatment."

For more information about DVS Sciences and the CyTOF-MAXPAR platform, please visit www.DVSsciences.com


About DVS Sciences, Inc.

DVS Sciences, Inc. manufactures and has global distribution of novel bioanalytical solutions for use in biomarker discovery, biological research and possible clinical applications. The patented multi-parameter solution comprises a high-throughput mass cytometer for quantitative individual cell analysis, CyTOF®, and a suite of MAXPAR® reagents, which include stable-isotope-tagged antibodies. The CyTOF - MAXPAR system overcomes the limitations of conventional flow cytometry, simplifies sample preparation and simultaneously identifies up to 100 biomarkers with high resolution and wide dynamic range. CyTOF systems are installed in leading laboratories across the U.S., Canada and Asia.
DVS Sciences has an R&D and manufacturing facility near Toronto, Canada, and its global headquarters is located in Sunnyvale, California.

MEDIA CONTACT:
Lynne Trowbridge, Daniel Gooch, Dimithri Wignarajah
College Hill Life Sciences
Tel: +44 20 7866 7866
Email: dvs@collegehill.com

Scott Tanner
CEO and Co-Founder
DVS Sciences, Inc.
Tel: +1 905-513-1704 ext 5921
Email: scott.tanner@DVSsciences.com


   
Record changed: 2016-03-19

Advertisement

Picture AB Sciex Berliner LCMSMS Symposium 2017 Middle 600x60px

More documents for Fluidigm (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 120x180px Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 120x180px Picture AB Sciex Berliner LCMSMS Symposium 2017 Right 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px